Defining the full therapeutic potential of recombinant growth factors in the post radiation-accident environment: The effect of supportive care plus administration of G-CSF

Health Physics

Volumn 89, Issue 5, 2005, Pages 546-555

  MacVittie, Thomas J ^a   Farese, Ann M ^a   Jackson III, William ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

Author keywords

Accidents, handling; Dogs; National Council on Radiation Protection And Measurements; Radiation effects

Indexed keywords

CEFOTAXIME; COBALT 60; GENTAMICIN; RECOMBINANT CYTOKINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH FACTOR; RINGER LACTATE SOLUTION;

ACUTE HEMATOPOIETIC SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; BLOOD DISEASE; CONFERENCE PAPER; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; FLUID THERAPY; HEMATOPOIETIC STEM CELL; LD 50; LETHAL DOSE; MYELOPOIESIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RADIATION ACCIDENT; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RADIATION RESPONSE; SUPPORTIVE CARE; SURVIVAL; THROMBOCYTE TRANSFUSION;

ACCIDENTS, RADIATION; ANIMALS; DOGS; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; LETHAL DOSE 50; NEUTROPHILS; RADIATION INJURIES; THROMBOCYTOPENIA; WHOLE-BODY IRRADIATION;

CANIS FAMILIARIS;

EID: 26844521492     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HP.0000173143.69659.5b     Document Type: Conference Paper

References (54)

1. Allen RG, Brown FA, Logic LC, Rovner DR, Wilson Jr. SG, Zellmer RW. Acute effects of gamma radiation in the primate. Radiat Res 12:532-559; 1960.
2. Allman D, Sambandam A, Kim S, Miller JP, Pagan A, Well D, Meraz A, Bhandoola A. Thymopoisis independent of common lymphoid progenitors. Nat Immunol 4:168-174; 2003.
3. Browne D, Weiss JF, MacVittie TJ, Pillai MV. Treatment of radiation injuries. In: Proceedings of the First Consensus Development Conference on the Treatment of Radiation Injuries. New York: Plenum Press; 1989: 5-10.
4. Cole LJ, Haire HM, Alpen EL. Partial shielding of dogs: effectiveness of small external epicondylar lead cuffs against lethal x-radiation. Radiat Res 32:54-63; 1967.
5. Dainiak N. Biological effects of radiation injury. In: Dainiak N, Schull WJ, Karkanitsa L, Aleinikova OA, eds. Radiation Injury and the Chernobyl Catastrophe. Miamisburg, OH: AlphaMed Press; 1996: 3-22.
6. Demetri GD. Targeted approaches for the treatment of thrombocytopenia. Oncologist 6:15-23; 2001.
7. Densow D, Kindler H, Baranov AE, Tibken B, Hofer EP, Fliedner TM. Criteria for the selection of radiation accident victims for stem cell transplantation. Stem Cells 15(Suppl 2):287-297; 1997.
8. Du X, Williams D. Interleukin-11: Review of molecular, cell biology, and clinical use. Blood 89:3897-3908; 1997.
9. Du XX, Neben T, Goldman S, Williams DA. Effects of recombinant interleukin-11 on hematopoietic reconstitution in transplant mice: acceleration of recovery of peripheral blood neutrophils and platelets. Blood 81:27-34; 1993.
10. Farese AM, Williams DE, Seiler FR, MacVittie TJ. Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage colony-stimulating factor in a primate model of radiation-induced marrow aplasia. Blood 82:3012-3018; 1993.
11. Farese AM, Hunt P, Grab LB, MacVittie TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clinical Investigation 97:2145-2151; 1996.
12. Farese A, MacVittie TJ, Lind LB, Smith WG, McKearn JP. The combined administration of daniplestim and MpL ligand augments the hematopoietic reconstitution observed with single cytokine administration in a nonhuman primate model of myelosuppression. In: Murphy MJ, Kutner DJ, eds. Thrombopoietin: from molecule to medicine. Miamisburg, OH: AlphaMed Press; 1998: 143-154.
13. Farese AM, Casey DB, Vigneulle RM, Siegel NR, Finn RF, Klover JA, Smith WG, McKearn JP, MacVittie TJ. A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. Stem Cells 19:514-521; 2001a.
14. Farese AM, Casey DB, Smith WG, Vigneulle RM, McKearn JP, MacVittie TJ. Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in nonhuman primate model of radiation-induced myelosuppression: Effect of schedule, dose, and route of administration. Stem Cells 19:522-533; 2001b.
15. Garner RJ, Phemister RD, Angleton GM, Lee AC, Thomassen RW. Effect of age on the acute lethal response of the beagle to cobalt-60 gamma radiation. Radiat Res 58:190-195; 1974.
16. Georges GE, Storb RF. Experimental and clinical experience with hematopoietic stem cell transplants. Stem Cells 15:73-94; 1997.
17. Hansen CL, Michaelson SM, Howland JW. Lethality of upper body exposure to x-radiation in beagles. Public Health Rep 76:242-246; 1961.
18. Hao J, Sun L, Huang H, Xiong G, Liu X, Qiu L, Chen G, Dong B, Li Y, Chen W, Buechler Y, Sun J, Shen C, Luo Q. Effects of recombinant human interleukin 11 on thrombocytopenia and neutropenia in irradiated rhesus monkeys. Radiat Res 162:157-163; 2004.
19. Hartley C, McElroy T, Sutherland W, Molineux G. Treatment with SD/01 relative to chemotherapy in mice. Exp Hematol 7(Suppl 1):192-193; 2000.
20. International Commission on Radiation Units and Measurements. Quantitative concepts and dosimetry in radiobiology. Bethesda, MD: ICRU; Report 30; 1979.
21. Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M, Cai B, Beach KJ, Loewy JW, Kaye JA. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 15:3368-3377; 1997.
22. Kimura T, Kaburaki H, Miyamoto S, Katayama J, Watanabe Y. Discovery of a novel thrombopoietin mimic agonist peptide. J Biochem 122:1046-1051; 1997.
23. Leonard JP, Quinto CM, Goldman SJ, Kozitza MK, Neben TY. Recombinant human interleukin-11(rhlL-11) stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. Blood 83:1499-1506; 1994.
24. MacVittie TJ, Monroy R, Vigneulle RM, Zeman GH, Jackson WE. The relative biological effectiveness of mixed fission-neutron-radiation on the hematopoietic syndrome in the canine: Effect of therapy on survival. Radiat Res 128:529-536; 1991.
25. MacVittie TJ, Weiss JF, Browne D. Advances in the treatment of radiation injuries. In: Proceedings of Second Consensus Development Conference on the Treatment of Radiation Injuries. Terrytown, NY: Elsevier Science Inc.; Advances in the Biosciences; 1993: 4-14.
26. MacVittie TJ, Farese AM, Grab LB, Hunt P. Effect of delayed administration of recombinant human megakaryocyte growth and development factor on hematopoietic reconstitution in nonhuman primates following radiation-induced marrow aplasia [abstract]. Exp Hematol 23:830; 1995.
27. MacVittie TJ, Farese AM, Herodin F, Grab LB, Baum CM, McKearn JP. Combination therapy of radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor. Blood 87:4129-4135; 1996a.
28. MacVittie TJ, Weiss JF, Browne D. Consensus summary on the treatment of radiation injuries. In: MacVittie TJ, Weiss JF, Browne D, eds. Advances in the Treatment of Radiation Injuries. Tarrytown, NY: Elsevier Sciences Inc.; 1996b: 325-346.
29. MacVittie T, Farese AM, Smith WG, Baum CM, Burton E, McKearn JP. Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood 95:837-845; 2000.
30. Maillie HD, Krasavage W, Mermagen H. On the partial body irradiation of the dog. Health Phys 12:883-887; 1966.
31. Nash RA, Schuening FG, Seidel K, Appelbaum FR, Boone T, Deeg HJ, Graham TC, Hackman R, Sullivan-Pepe M, Storb R. Effect of recombinant canine granulocyte-macrophage colony-stimulating factor of hematopoietic recovery after otherwise lethal total body irradiation. Blood 83:1963-1970; 1994.
32. Nash RA, Seidel K, Storb R, Slichter S, Schuening FG, Appelbaum FR, Becker AB, Bolles L, Deeg HJ, Graham T, Hackman RC, Burstein SA. Effects of rhIL-11 on normal dogs and after sublethal radiation. Experimental Hematol 23:389-396; 1995.
33. National Research Council. The Institute of Laboratory Animal Resources, Guide for the care and use of laboratory animals. Washington, DC: National Institutes of Health; 1996.
34. Neelis KJ, Hartong SCC, Egeland T, Thomas GR, Eaton DL, Wagemaker G. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys. Blood 90:2565-2573; 1997a.
35. Neelis KJ, Dubbelman YD, Qingliang L, Thomas GR, Eaton DL, Wagemaker G. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Experimental Hematol 25:1084-1093; 1997b.
36. Norris WP, Fritz TE, Rehfeld CE, Poole CM. The response of the beagle dog to cobalt-60 gamma radiation: Determination of the LD 50/30 and description of associated changes. Radiat Res 35:681-708; 1968.
37. Patchen ML, MacVittie TJ, Williams JL, Schwartz GN, Souza LM. Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression. Blood 77:472-480; 1991.
38. Ricks RC, Fry SA. The medical basis for radiation accident preparedness II: Clinical experience and follow-up since 1979. In: The Medical Basis for Radiation Accident Preparedness. New York: Elsevier Science, Inc.; 1988: 10-20.
39. Ricks RC, Berger ME, O'Hara F. The medical basis for radiation accident preparedness IV: Clinical care of victims. Washington, DC: Parthenon Publishers; 2001.
40. Schlerman FJ, Bree AG, Kaviani MD, Nagle SL, Donnelly LH, Mason LE, Schaub RG, Grupp SA, Goldman SJ: Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates. Stem Cells 14:517-532; 1996.
41. Schuening FG, Storb R, Goehle S, Graham TC, Appelbaum FR, Hackman R, Souza LM. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. Blood 74:1308-1313; 1989.
42. Schuening FG, Appelbaum FR, Deeg HJ, Sullivan-Pepe M, Graham TC, Hackman R, Zsebo KM, Storb R. Effects of recombinant canine stem cell factor, a c-kit ligand and recombinant granulocyte colony stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood 81:20-26; 1993.
43. Shibuya K, Akahori H, Takahashi K, Tahara E, Kato T, Miyazaki H. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. Blood 91:37-45; 1998.
44. Shively JN, Michaelson SM, Howland JW. The responses of dogs to bilateral whole-body cobalt-60 irradiation. I. Lethal dose determinations. Radiat Res 9:445-450; 1958.
45. Smith J. Tolerability and side-effect profile of rhIL-11. Oncol 14:41-42; 2000.
46. Storb R, Raff RF, Graham T, Appelbaum FR, Deeg HJ, Schuening FG, Shulman H, Pepe M. Marrow toxicity of fractionated versus single dose total body irradiation is identical in a canine model. Int J Radiat Oncol Biol Phys 26:275-283; 1993.
47. Sureda A, Valls A, Kadar E, Algara M, Ingles-Esteve J, Bigas A, Jaume M, Lacruz M, Tobajas LM, Rutllant M, Garcia J. A single dose of granulocyte colony stimulating factor modifies radiation-induced death in B6D2F1 mice. Exp Hematol 21:1605-1607; 1993.
48. Tanikawa S, Nose M, Yoshiro A, Tsuneoka K, Shikita M, Nara N. Effects of recombinant human granuloctye colony-stimulating factor on the hematologic recovery and survival of irradiated mice. Blood 76:445-449; 1990.
49. Tepler I, Elias L, Smith JW II, Hussein M, Rosen G, Chang AY, Moore JO, Gordon MS, Kuca B, Beach KJ, Loewy JW, Garnick MB, Kaye JA. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607-3614; 1996.
50. Tullis JL, Chambers FW, Morgan JE, Zeller JH. Mortality in swine and dose distribution studies in phantoms exposed to supervoltage radiation. Am J Roentgenol 67:620-627; 1952.
51. Tullis JL, Lanson BG, Madden SG. Mortality in swine exposed to gamma radiation from an atomic bomb source. Radiol 62:409-415; 1954.
52. U.S. Department of Health and Human Services. 21 CFR parts 314 and 601-New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Washington, DC: U.S. Government Printing Office; 67(105) FR 37988-37998; 2002.
53. Wang RIH, Davidson DE. Experimental conditions for acute whole-body irradiation of dogs with cobalt-60. U.S. Army Medical Research Laboratory; 1961: 483-487.
54. Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, Dickerson WE, Tsu H, Confer DL, Coleman CN, Seed T, Lowry P, Armitage JO, Dainiak N. Strategic National Stockpile Radition Working Group. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Annals Intern Med 140:1037-1051; 2004.